MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Neurocrine Biosciences Inc

Fermé

SecteurSoins de santé

133.56 1.73

Résumé

Variation du prix de l'action

24h

Actuel

Min

130.07

Max

134.03

Chiffres clés

By Trading Economics

Revenu

-95M

7.9M

Ventes

-55M

573M

P/E

Moyenne du Secteur

45.807

39.564

BPA

0.7

Marge bénéficiaire

1.38

Employés

1,800

EBITDA

-146M

24M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+23.98% upside

Dividendes

By Dow Jones

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.7B

13B

Ouverture précédente

131.83

Clôture précédente

133.56

Sentiment de l'Actualité

By Acuity

50%

50%

154 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Neurocrine Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 janv. 2025, 00:03 UTC

Actions en Tendance

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 mars 2025, 09:30 UTC

Actualités

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13 août 2024, 11:30 UTC

Actualités

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Comparaison

Variation de prix

Neurocrine Biosciences Inc prévision

Objectif de Prix

By TipRanks

23.98% hausse

Prévisions sur 12 Mois

Moyen 162.71 USD  23.98%

Haut 192 USD

Bas 115 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

22 ratings

20

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

109.55 / 121.61Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

154 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.